Low serum neurofilament light chain values identify optimal responders to dimethyl fumarate in multiple sclerosis treatment

Abstract Serum neurofilament light chains (sNfL) are biomarkers of disease activity in multiple sclerosis (MS), but their value to predict response to treatment, and their association with patient immunological profile, need to be further explored. We studied 80 relapsing–remitting MS patients initi...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Paulette Esperanza Walo-Delgado, Susana Sainz de la Maza, Noelia Villarrubia, Enric Monreal, Silvia Medina, Mercedes Espiño, José Ignacio Fernández-Velasco, Eulalia Rodríguez-Martín, Ernesto Roldán, Daniel Lourido, Alfonso Muriel, Jaime Masjuan-Vallejo, Lucienne Costa-Frossard, Luisa María Villar
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/8c728d8ae2de49b8accdc64e3ffacaf7
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:8c728d8ae2de49b8accdc64e3ffacaf7
record_format	dspace
spelling	oai:doaj.org-article:8c728d8ae2de49b8accdc64e3ffacaf72021-12-02T13:41:10ZLow serum neurofilament light chain values identify optimal responders to dimethyl fumarate in multiple sclerosis treatment10.1038/s41598-021-88624-72045-2322https://doaj.org/article/8c728d8ae2de49b8accdc64e3ffacaf72021-04-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-88624-7https://doaj.org/toc/2045-2322Abstract Serum neurofilament light chains (sNfL) are biomarkers of disease activity in multiple sclerosis (MS), but their value to predict response to treatment, and their association with patient immunological profile, need to be further explored. We studied 80 relapsing–remitting MS patients initiating dimethyl fumarate (DMF) treatment. sNfL levels were explored at baseline and at 3, 6 and 12 months by single molecule array. Blood lymphocyte subsets were measured at baseline and at 6 months by flow cytometry. Patients were followed a year and classified as NEDA (no evidence of disease activity) or ODA (ongoing disease activity). NEDA patients had lower sNfL levels at baseline (p = 0.0001), and after three (p = 0.004) and six (p = 0.03) months of DMF treatment. Consequently, low baseline sNfL values (≤ 12 pg/ml) increased the probability of NEDA (OR 5.8; CI 1.82–15.6; p = 0.002, after correcting by disease activity in the previous year), and associated with significant reductions of central memory CD4+ T lymphocytes, interferon-gamma+ CD8+ T lymphocytes, Natural Killer T cells, and memory B cells upon DMF treatment, being the highest differences in memory B cells (p < 0.0001). This shows that low baseline sNfL values identify MS patients with higher probability of optimal response to DMF and of a reduction in effector immune cells.Paulette Esperanza Walo-DelgadoSusana Sainz de la MazaNoelia VillarrubiaEnric MonrealSilvia MedinaMercedes EspiñoJosé Ignacio Fernández-VelascoEulalia Rodríguez-MartínErnesto RoldánDaniel LouridoAlfonso MurielJaime Masjuan-VallejoLucienne Costa-FrossardLuisa María VillarNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-8 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Paulette Esperanza Walo-Delgado Susana Sainz de la Maza Noelia Villarrubia Enric Monreal Silvia Medina Mercedes Espiño José Ignacio Fernández-Velasco Eulalia Rodríguez-Martín Ernesto Roldán Daniel Lourido Alfonso Muriel Jaime Masjuan-Vallejo Lucienne Costa-Frossard Luisa María Villar Low serum neurofilament light chain values identify optimal responders to dimethyl fumarate in multiple sclerosis treatment
description	Abstract Serum neurofilament light chains (sNfL) are biomarkers of disease activity in multiple sclerosis (MS), but their value to predict response to treatment, and their association with patient immunological profile, need to be further explored. We studied 80 relapsing–remitting MS patients initiating dimethyl fumarate (DMF) treatment. sNfL levels were explored at baseline and at 3, 6 and 12 months by single molecule array. Blood lymphocyte subsets were measured at baseline and at 6 months by flow cytometry. Patients were followed a year and classified as NEDA (no evidence of disease activity) or ODA (ongoing disease activity). NEDA patients had lower sNfL levels at baseline (p = 0.0001), and after three (p = 0.004) and six (p = 0.03) months of DMF treatment. Consequently, low baseline sNfL values (≤ 12 pg/ml) increased the probability of NEDA (OR 5.8; CI 1.82–15.6; p = 0.002, after correcting by disease activity in the previous year), and associated with significant reductions of central memory CD4+ T lymphocytes, interferon-gamma+ CD8+ T lymphocytes, Natural Killer T cells, and memory B cells upon DMF treatment, being the highest differences in memory B cells (p < 0.0001). This shows that low baseline sNfL values identify MS patients with higher probability of optimal response to DMF and of a reduction in effector immune cells.
format	article
author	Paulette Esperanza Walo-Delgado Susana Sainz de la Maza Noelia Villarrubia Enric Monreal Silvia Medina Mercedes Espiño José Ignacio Fernández-Velasco Eulalia Rodríguez-Martín Ernesto Roldán Daniel Lourido Alfonso Muriel Jaime Masjuan-Vallejo Lucienne Costa-Frossard Luisa María Villar
author_facet	Paulette Esperanza Walo-Delgado Susana Sainz de la Maza Noelia Villarrubia Enric Monreal Silvia Medina Mercedes Espiño José Ignacio Fernández-Velasco Eulalia Rodríguez-Martín Ernesto Roldán Daniel Lourido Alfonso Muriel Jaime Masjuan-Vallejo Lucienne Costa-Frossard Luisa María Villar
author_sort	Paulette Esperanza Walo-Delgado
title	Low serum neurofilament light chain values identify optimal responders to dimethyl fumarate in multiple sclerosis treatment
title_short	Low serum neurofilament light chain values identify optimal responders to dimethyl fumarate in multiple sclerosis treatment
title_full	Low serum neurofilament light chain values identify optimal responders to dimethyl fumarate in multiple sclerosis treatment
title_fullStr	Low serum neurofilament light chain values identify optimal responders to dimethyl fumarate in multiple sclerosis treatment
title_full_unstemmed	Low serum neurofilament light chain values identify optimal responders to dimethyl fumarate in multiple sclerosis treatment
title_sort	low serum neurofilament light chain values identify optimal responders to dimethyl fumarate in multiple sclerosis treatment
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/8c728d8ae2de49b8accdc64e3ffacaf7
work_keys_str_mv	AT pauletteesperanzawalodelgado lowserumneurofilamentlightchainvaluesidentifyoptimalresponderstodimethylfumarateinmultiplesclerosistreatment AT susanasainzdelamaza lowserumneurofilamentlightchainvaluesidentifyoptimalresponderstodimethylfumarateinmultiplesclerosistreatment AT noeliavillarrubia lowserumneurofilamentlightchainvaluesidentifyoptimalresponderstodimethylfumarateinmultiplesclerosistreatment AT enricmonreal lowserumneurofilamentlightchainvaluesidentifyoptimalresponderstodimethylfumarateinmultiplesclerosistreatment AT silviamedina lowserumneurofilamentlightchainvaluesidentifyoptimalresponderstodimethylfumarateinmultiplesclerosistreatment AT mercedesespino lowserumneurofilamentlightchainvaluesidentifyoptimalresponderstodimethylfumarateinmultiplesclerosistreatment AT joseignaciofernandezvelasco lowserumneurofilamentlightchainvaluesidentifyoptimalresponderstodimethylfumarateinmultiplesclerosistreatment AT eulaliarodriguezmartin lowserumneurofilamentlightchainvaluesidentifyoptimalresponderstodimethylfumarateinmultiplesclerosistreatment AT ernestoroldan lowserumneurofilamentlightchainvaluesidentifyoptimalresponderstodimethylfumarateinmultiplesclerosistreatment AT daniellourido lowserumneurofilamentlightchainvaluesidentifyoptimalresponderstodimethylfumarateinmultiplesclerosistreatment AT alfonsomuriel lowserumneurofilamentlightchainvaluesidentifyoptimalresponderstodimethylfumarateinmultiplesclerosistreatment AT jaimemasjuanvallejo lowserumneurofilamentlightchainvaluesidentifyoptimalresponderstodimethylfumarateinmultiplesclerosistreatment AT luciennecostafrossard lowserumneurofilamentlightchainvaluesidentifyoptimalresponderstodimethylfumarateinmultiplesclerosistreatment AT luisamariavillar lowserumneurofilamentlightchainvaluesidentifyoptimalresponderstodimethylfumarateinmultiplesclerosistreatment
_version_	1718392630726885376

Low serum neurofilament light chain values identify optimal responders to dimethyl fumarate in multiple sclerosis treatment

Ejemplares similares